PMC

(a) Q-RTPCR analysis of RNA expression of 6 genes involved in NF-kB activation in OCI-AML3 cells after JMJD3 knock-down. (b) Immuno-histochemical analysis of phospho-p65 in the OCI-AML3 cells with JMJD3 knock-down (Top panel) and in control cells (Bottom panel). (c) H3K4me3 CHIP-PCR analysis of IL8RB, TYROBP, and FPR2 in the OCI-AML3 cells after JMJD3 knock-down. (d) H3K27me3 CHIP-PCR analysis of IL8RB in the OCI-AML3 cells after JMJD3 knock-down.

(a) Immuno-histochemical analysis of phospho-p65 in MDS (Top panel) and controls (Bottom panel) bone marrow CD34+ cells. (b) Knock-down of C5AR1, FPR2, TYROBP and PTAFR in OCI-AML3 cells. (c) Immuno-histochemical analysis of phospho-p65 in the OCI-AML3 cells after knock-down of the 4 genes described above (Left panel) in comparison to control siRNA transfected cells (Right panel).

(a) Representative examples of H3K4me3 identified by CHIP-Seq in 11 genes in MDS (top) and control (bottom) BM CD34+ cells. Comparison between MDS and control samples indicate increased levels of H3K4me3 in the promoters of these genes in MDS CD34+ cells. (b) Logarithmic representation of Q-RTPCR results of 16 genes identified by CHIP-Seq in MDS and control CD34+ cells. These results confirm increased RNA expression in genes marked by higher levels of promoter H3K4me3 in MDS.

(a) Logarithmic representation of JMJD3 Q-RTPCR results in MDS and control CD34+ cells in 121 MDS CD34+ samples. (b) Immuno-histochemical analysis of JMJD3 in cytospins of MDS (Left 3 panels: Top 2 with strong JMJD3 staining and Bottom 1 with weak JMJD3 staining) and controls (Right 2 panels: both with weak JMJD3 staining) bone marrow CD34+ cells. (c) Q-RTPCR analysis of JMJD3 RNA expression in OCI-AML3 cells transfected with siRNAs targeting C5AR1, FPR2, TYROBP and PTAFR or controls. (d) p65 CHIP-PCR analysis of JMJD3 promoter in the OCI-AML3 cells transfected with the siRNAs targeting C5AR1, FPR2, TYROBP and PTAFR or controls.

(a) Numbers of myeloid colonies (CFU-G/M) and erythroid colonies (CFU-E) formed in methocult culture two weeks after transduction of JMJD3-shRNA and control shRNA in BM CD34+ cells isolated from patients with lower-risk MDS (low-risk and intermediate-1). (b) Representative microphotographs of colonies formed in methocult plates after transduction of control shRNA (Left panel) and JMJD3-shRNA (Right panel). Red arrows point to CFU-E. (c) Q-RTPCR analysis of the RNA levels of CD71, EPOR and GYPA in cells collected from total colonies after shRNA transduction and methocult assays.

(a-c) Effect of mRNA expression of NCF2, AQP9 and MEFV on survival of patients with MDS. (d) Innate immunity stimulation derived from stroma, chronic inflammation or hematopoietic cells either in a para or autocrine fashion result in NF-kB activation in MDS CD34+ cells. NF-kB activation then triggers expression of multiple other effectors such as cytokines and importantly JMJD3. JMJD3 is a histone demethylase that contributes to the perpetuation of innate immunity signal and NF-kB activation. Signaling via this pathway probably cooperates with other known genetic and epigenetic lesions known to occur in MDS cells and contribute to bone marrow failure and transformation to AML that characterized MDS. Further analysis of this pathway could result in the development of inhibitors with therapeutic potential.